HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CBD Will Be US FDA’s ‘One’ Lawful Hemp Compound, House Appropriators Anticipate

Executive Summary

Reference in report accompanying House Appropriation Committee bill for FDA FY2023 budget isn’t binding and wasn’t appropriators’ first mention of agency’s response to de-scheduling hemp as a controlled substance. But their ’ statement was more pointed than in previous appropriation reports.

You may also be interested in...



Food In Capitol Hill's Lawful Hemp Recipe, But CBD, Delta-8 On FDA Unsafe Food Ingredients Menu

All legislation introduced in Congress on establishing hemp as lawful dietary ingredient also would extend change to food ingredients. Two hemp derivatives among 12 ingredients on FDA’s first list of food ingredients unsafe for use in food.

Details Dished On Regulatory Pathway US FDA’s Developing For Lawful Hemp In Supplements

Pathway separate from FDA’s regulation of drugs and food would include rules on content limits, labeling, disclosure of ingredients– including assurances of no contaminants, and requirements to mitigate accidental ingestion.

Will DEA Saying Synthetic THCs Are Controlled Substances Help Deliver Lawful Hemp Answer?

DEA’s explanation delta-8 THC acetate isn’t hemp, along with FDA’s hemp and cannabis policies chief saying it and other cannabis derivatives aren’t hemp, should simplify decision on lawful use of hemp in non-drug products subject to FDA’s regulatory oversight.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152722

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel